CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, ...

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

The University of Chicago will sell one of its valuable research centers for $375 million as it attempts to cope with various ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $67.74, demonstrating a -6.98% change from the preceding day's closing price. This change lagged the S&P 500's 0.01% gain on the day.

Morningstar has agreed to buy the Center for Research in Security Prices, or CRSP, a provider of historical stock-market data and indexes, from the University of Chicago for $375 million.

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

The latest update is out from Morningstar ( (MORN) ).

The University of Chicago and Morningstar, Inc. have reached an agreement for Morningstar to acquire the UChicago-affiliated Center for Research in Security Prices (CRSP), a leading source of ...

The University of Chicago is selling its Center for Research in Security Prices to the investment firm Morningstar for $375 million. The CRSP was created at what is now the U of C's Booth School of ...

Morningstar Inc. (NASDAQ:MORN) is one of the best buy-the-dip stocks to buy, according to analysts. On September 23, the ...